Month-6 primary outcomes of the READ-3 study (Ranibizumab for Edema of the mAcula in Diabetes-Protocol 3 with high dose)

Eye (Basingstoke)

Volumn 29, Issue 12, 2015, Pages 1538-1544

  Do, D V ^a   Sepah, Y J ^a   Boyer, D ^b   Callanan, D ^c   Gallemore, R ^d   Bennett, M ^e   Marcus, D M ^f   Halperin, L ^g   Sadiq, M A ^a   Rajagopalan, N ^a   Campochiaro, P A ^h   Nguyen, Q D ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b Retina Vitreous Assoct   (United States)

^c Texas Retina   (United States)

^d Retina Macula Institute   (United States)

^e Retina Institute of Hawaii   (United States)

^f Southeast Retina Center   (United States)

^g Retina Group of Florida   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; STEROID; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DIABETIC MACULAR EDEMA; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG MEGADOSE; ENDOPHTHALMITIS; FEMALE; HEART DISEASE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; INCIDENCE; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOMYELITIS; RANDOMIZED CONTROLLED TRIAL; RETINA EDEMA; RETINA MACULA LUTEA; THORAX PAIN; URINARY TRACT INFECTION; VISUAL ACUITY; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETIC RETINOPATHY; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PATHOPHYSIOLOGY; RETINA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; DIABETIC RETINOPATHY; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RANIBIZUMAB; RETINA; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84949599724     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2015.142     Document Type: Article

References (7)

1. Nguyen QD, Tatlipinar S, Shah SM, Haller JA, Quinlan E, Sung J et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006; 142(6): 961-969.
2. Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D et al. Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2009; 116(11): 2175-81 e1.
3. Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2010; 117(11): 2146-2151.
4. Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117(6): 1064-1077 e35.
5. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118(4): 615-625.
6. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012; 119(4): 789-801.
7. Do DV, Nguyen QD, Khwaja AA, Channa R, Sepah YJ, Sophie R et al. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmol 2013; 131(2): 139-145.